Harrow Health (HROW) Scheduled to Post Quarterly Earnings on Monday

Harrow Health (NASDAQ:HROW) is set to issue its quarterly earnings data after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Harrow Health (NASDAQ:HROW) last released its quarterly earnings results on Tuesday, March 19th. The company reported ($0.27) earnings per share for the quarter. The firm had revenue of $36.36 million for the quarter, compared to the consensus estimate of $37.65 million. Harrow Health had a negative net margin of 18.75% and a negative return on equity of 29.48%. On average, analysts expect Harrow Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Harrow Health Price Performance

NASDAQ HROW opened at $10.38 on Monday. The business’s fifty day moving average price is $11.47 and its 200-day moving average price is $11.00. The stock has a market capitalization of $367.24 million, a price-to-earnings ratio of -13.84 and a beta of 0.58. The company has a debt-to-equity ratio of 2.60, a current ratio of 2.83 and a quick ratio of 2.61. Harrow Health has a 1-year low of $7.60 and a 1-year high of $28.25.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Craig Hallum began coverage on Harrow Health in a report on Thursday, April 11th. They set a “buy” rating and a $24.00 price target on the stock. B. Riley reduced their price objective on Harrow Health from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, March 22nd.

Insiders Place Their Bets

In other Harrow Health news, CEO Mark L. Baum purchased 9,000 shares of the business’s stock in a transaction on Friday, March 22nd. The stock was acquired at an average price of $11.59 per share, for a total transaction of $104,310.00. Following the purchase, the chief executive officer now owns 2,137,525 shares of the company’s stock, valued at approximately $24,773,914.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Opaleye Management Inc. acquired 20,000 shares of the business’s stock in a transaction dated Thursday, April 25th. The stock was purchased at an average price of $9.97 per share, for a total transaction of $199,400.00. Following the completion of the transaction, the insider now directly owns 3,815,000 shares in the company, valued at approximately $38,035,550. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Mark L. Baum acquired 9,000 shares of the business’s stock in a transaction dated Friday, March 22nd. The shares were purchased at an average price of $11.59 per share, with a total value of $104,310.00. Following the transaction, the chief executive officer now owns 2,137,525 shares of the company’s stock, valued at $24,773,914.75. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 170,715 shares of company stock worth $1,864,011. Corporate insiders own 13.60% of the company’s stock.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.